References

1. Borel JF. The history of cyclosporin A and its significance. In: White DJG, ed., Cyclosporin A: Proceedings of an International Conference on Cyclosporin A, Cambridge, September 1981. Amsterdam/New York: Elsevier/Biomedical Press, 1982;5—17.

2. Fathman CG, Myers BD. Cyclosporine therapy for autoimmune disease. N Engl J Med 1992;326:1693-1694.

3. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.

4. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992;339: 324-328.

5. Van Joost TH, Heule EM, Marks, JM et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermat 1994;130:634-640.

6. Toubi E, Blant A, Kessel A, Goland TD. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997;52:312-316.

7. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficay and tolerability of a microemulsion-based formulation. (Neoral) Drugs 1995;50:924-941.

8. Mallat A. Cytochrome P-450IIIA, Ciclosporine et interactions medicamentouses. Gastroenterol Clin Biol 1992;16:295-298.

9. Handshumacher RE, Harding MW, Rice J, Drugge RJ. Cyclophilin: a specific cytosolic binding protein for cyclosporine A. Science 1985;226:544-547.

10. Takahashi N, Hayano T, Suzuki M. Peptydyl-prolyl eis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989;337:473^175.

11. Ho S, Clipstone N, Timmerman L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:S40-S45.

12. Rao A, Luo C, Hoagan PG. Transcription factors of the NFAT family: regulation and function. Ann Rev Immunol 1997;15:707-747.

13. Lancki DW, Kaper BP, Fitch FW. The requirements for triggering of lysis by cytolytic T lymphocyte clones.II. Cyclosporin A inhibits TCR-mediated exostosis by cloned CTL. J Immunol 1989;142:416-424.

14. Burke JF, Pirsche JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporin A in renal transplant recipients. N Engl J Med 1994;331:358-363.

15. Olshan AF, Mattison DR, Zwanenburg TS. International commission for protection against environmental mutagens and carcinogens. Cyclosporin A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working group on the genotoxicity of cyclosporin A, 18 August 1993. MutatRes 1994;317:163-173.

16. Ryffel B. The carcinogenicity of cyclosporin. Toxicology 1992;73:1-22.

17. Matter BE, Donatsch P, Racine RR. Genotoxicity evaluation of cyclosporin A, a new immunosuppressive agent. Mutat Res 1982:105:257.

18. Zwanenburg TSB, Suter W, Matter BE. Absence of genotoxic potential for cyclosporin in experimental system. Trans Proc 1988;20:435.

19. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long term immunosuppression in kidney graft recipi ents on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-628. Klein G, Purtillo D. Summary: Symposium on EBV induced lymphoproliferative diseases in immunodefi-cient patients. Cancer Res 1981;41:4302-4304. Matas AJ, Simmons RL, Najaran JS. Chronic antigenic stimulation, herpes virus infection and cancer in transplant recipients. Lancet 1975:i;1277. Nalesnik MA, JafTe R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression. Am J Pathol 1988;133:173-192. Zijlmans JMJM, Van Rijthoven AWAM, Kluin PM, et al. Epstein Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporin. N Engl J Med 1992: 326:1363. Ferraccioli GF, Casatta L, Bartoli E, et al. EBV-associated Hodgkin's lymphoma in a RA patient treated with methotrexate and CyA. Arthrit Rheumatol 1995:6:867-868.

York LJ, Qualtiere LF. Cyclosporin abrogates virus-specific T cell control of EBV induced B cell lym-phoproliferation. Viral Immunol 1990;3:127-136. Bird GA, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of EBV-induced B-cell lines. Nature 1981;289:300. Crawford DH, Edwards JM. Immunity to EBV in cyclosporin A-treated renal allograft recipients. Lancet 1981;i:1469.

Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphoma and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;i:583—587.

Kamel OW, Van de Rijn M, Weiss LM. Reversible lymphomas associated with EBV occurring during methotrexate therapy for rheumatoid arthritis and der-matomyositis. N Engl J Med 1993:328:1317-1321. Vogl M, Griesmacher A, Grimm M, Klepetko W, Muller MM. Tissue polypeptide specific antigen for the detection of lymphoproliferative diseases induced by cyclosporin. J Clin Pathol 1995:48:1039-1044. Wilkinson Ah, Smith JL, Hunsicker LG, et al. Increased frequency of post-transplant lymphomas in patients treated with cyclosporin, azathioprine and prednisone. Transplantation 1989;47:293. Gamier JL, Berger F, Betuel H, et al. Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation. Nephrol Dial Transplant 1989;4:818.

Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporin A. J Autoimmunity 1989;2:723-731.

Penn I. The changing pattern of post-transplant malignancies. Transplant Proc 1991 ;23:1101-1103.

35. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997;71:517-520.

36. Gaya SBM, Rees AJ, Lechler G, Williams G, Mason PD. Malignant disease in patients with long term renal transplants. Transplantation 1995;59:1705-1709.

37. Hiesse C, Rieu P, Kriaa JR, et al. Malignancy after renal transplantation: analysis of incidence and risk factor in 1700 patients followed during a 25-year period. Transplant Proc 1997;29:831-833.

38. European multicentre trial group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicenter trial. Lancet 1983;ii:986.

39. The Canadian multicenter transplant study group: a randomized clinical trial of cyclosporin in cadaveric renal transplant. N Engl J Med 1983;309:809.

40. Kelly GE, Mieckle W, Sheil AGR. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987;44:429.

41. Carsons S. The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 1997;24:360-372.

42. Kinlen LK Malignancy in autoimmune diseases. J Autoimmun 1992;5 suppl A:363-371.

43. Valesini G, Priori R, Bavoillot D, et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997;24:2376-380.

44. Petterson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with Systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-439.

45. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with DM: a population based study. J Rheumatol 1995, 22: 1300-1303.

46. Ferraccioli GF, Bartoli E. Autoimmunity and clonal B cell expansion. Clin Exp Rheum 1996;14(suppl 14):S19.

47. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-696.

48. Tennis P, Andrews E, Bombardier C, et al. Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada. J Clin Epidemiol 1993;46:685-695.

49. Gridley G, MC Laughlin JK, Ekbom A, et al. Incidence of cancer in patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311.

50. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthrit Rheumatol 1997;40:1580-1587.

Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immuno suppressive treatment. Am J Med 1985;78(suppl 1A):44-49.

Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthrit Rheumatol 1996;39:1006-1015.

Arellano F, Krupp P. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheum 1993;32:72-75.

Yoccum DE, Wilder RL. Cyclosporin A in systemic sclerosis. Am J Med 1987;83:369-370. Appleboon T, Itzkowitch D. Cyclosporin in successful control of rapidly progressive scleroderma. JAMA 1986;82:886-887.

Knop J, Brosman G. Cyclosporin in treatment of progressive systemic sclerosis. In: Schindler R, ed., Cyclosporin in Autoimmune Diseases. Berlin: SpringerVerlag, 1985; 199-201.

Zachariae M, Halkier-Sorensen L, Heickendorf, et al. Cyclosporin A treatment of systemic sclerosis. Br J Rheumatol 1990;122:677-681. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporin in systemic sclerosis. Arthrit Rheumatol 1993;36:75-83.

Gissilinger H, Burghuber OC, Stacher G, et al. Efficacy of Cyclosporin A in systemic sclerosis. Clin Exp Rheum 1991;9:383-390.

Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthrit Rheumatol 1993;36:460-464. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patient with systemic sclerosis. Cancer 1995;76:910-914. Merot Y, Miescher PA, Balsiger F, et al. Cutaneous malignant melanomas occurring under cyclosporin A therapy: a report of two cases. Br J Dermatol 1990;123:237-239.

Menon S, Snaith ML, Isemberg DA. The association of malignancy with SLE: an analysis of 150 patients under long term review. Lupus 1993;2:177-181. Lopez-Dupla M, Khamashta M, Pintado Garcia V, et al. Malignancy in SLE: a report of five cases in a series of 96 patients. Lupus 1993;2:377-380. Bhalla R, Ajmani HS, Kim WW, et al. Systemic lupus erythematosus and non-Hodgkin's lymphoma. J Rheumatol 1993;29:1316-320. Ramsey-Goldman R, Mattai SA, Chiu YL, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Inv Med 1998;46:217-222.

Petterson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-439.

68. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthrit Rheumatol 1996;39:1050-1054.

69. Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in female patients with systemic lupus erythematosus. J Rheumatol 1995;22:1478-1482.

70. Nyberg G, Eriksson O, Westberg NG. Increased incidence of cervical atypia in women with SLE treated with chemotherapy. Arthrit Rheumatol 1981 ;24. 648650.

71. Miescher PA, Miescher A. Combined cyclosporin-steroid treatment of systemic lupus erythematosus. In: Schneider R, ed., Cyclosporin in Autoimmune Disease. Berlin: Springer-Verlag, 1985.

72. Tokuda M, Kurata N, Mizoguchi A, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthrit Rheumatol 1994;37:551-558.

73. Feutren G, Querin S, Noel LH, et al. Effects of cyclosporin in severe systemic lupus erythematosus. J Pediatr 1987;111:1063-1068.

74. Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996;35:669-675.

75. Caccavo D, Laganä B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin X. Arthrit Rheumatol 1997;40:27-35.

76. Mellmkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthrit Rheumatol 1997;40:761-768.

77. Mueller W, Herrmann B. Cyclosporin A for Psoriasis. N Engl J Med 1979 301:555.

78. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporin for plaque-type psoriasis-results of a multidose, double blind trial. N Engl J Med 1991;324:277-284.

79. Griffiths CEM, Powells AV, McFadden J, et al. Long term cyclosporin for psoriasis. Br J Dermatol 1989;120:253-260.

80. Krupp P, Monka C. Side-effects profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990;36(suppl):47-56.

81. Green C, Hawk JLM. Cutaneous malignancy related to cyclosporin A therapy. Clin Exp Dermatol 1993;18:30-31.

82. Bos JD. Meinardi MMHN. Two distinct squamous cell carcinomas in a psoriasis patient receiving low-dose cyclosporin maintenance treatment. J Am Acad Dermatol 1989;21:1305-1306.

83. Oxholm A, Thomsen K, Menne T. Squamous cell carcinoma in relation to cyclosporin therapy of non-malignant skin disorders. Acta Dermato Vener (Stockholm) 1988;69:89-90.

84. Feutren G, Laburte C, Krupp P. Safety and tolera-bility of cyclosporin A in psoriasis. In Wolff K, ed., Cyclosporin A and the Skin. Proceedings of the Satellite Symposium to the 2nd Congress of the European Acad Dermatol Venereol, Athens (Greece) 12 October 1991. London Royal Society of Medicine Services, 1992;3-12.

85. Mihatsch MJ, Wolff K. Consensus conference on cyclosporin A for psoriasis. Br J Dermatol 1992;126:621-623.

86. Grossmann RM, Maugee E, Dubertret L. Cervical intraepithelial neoplasia in a patient receiving long-term cyclosporine for the treatment of severe plaque psoriasis. Br J Dermatol 1996;135:147-148.

87. Nussenblatt RB, Salinas-Carmona MC, Gery I, et al.

Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophtalmol 1982;100:1462.

88. BenEzra D, Nussenblatt RB, Timonen P. Optimal use of CyA in endogenous uveitis Berlin, SpringerVerlag.

89. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporin for the treatment of Crohn's diseases. N Engl J Med 1994;330:1846-1851.

90. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.

91. Collaborative study group of Sandimmun in nephrotic syndrome. Safety and tolerability of cyclosporin A in idiopathic nephrotic syndrome. Clin Nephrol 1991;35(suppl 1):S48-S60.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment